Does Sapropterin Cure PKU?
No, sapropterin (Kuvan) does not cure phenylketonuria (PKU). It is an oral synthetic form of tetrahydrobiopterin (BH4), a cofactor that helps the enzyme phenylalanine hydroxylase (PAH) break down phenylalanine (Phe) in some patients. Only about 20-30% of PKU patients—those responsive to BH4—see enough Phe reduction to loosen dietary restrictions, but lifelong treatment and monitoring remain necessary.[1][2]
How Does Sapropterin Work in PKU?
PKU stems from PAH mutations causing toxic Phe buildup. Sapropterin boosts residual PAH activity chemically, lowering blood Phe by 30% or more in responders after a trial dose. Non-responders get no benefit and must stick to strict low-Phe diets. It does not fix the genetic defect or restore normal enzyme function permanently.[1][3]
Who Responds and What Results Look Like?
Response testing involves 8 days of sapropterin with Phe monitoring. Responders (often milder PAH mutations like those in BH4-responsive PKU) maintain lower Phe on 10-20 mg/kg daily doses, improving diet tolerance and neurocognitive outcomes in kids. Adults and severe cases rarely respond fully. Studies show sustained Phe control in responders over years, but stopping the drug reverses benefits within days.[2][4]
What Limits Sapropterin as a Cure?
- Not universal: Only partial responders qualify; 70%+ need diet alone.
- Dependency: Daily dosing required; no gene repair.
- Side effects: Include headache, runny nose, and rare anaphylaxis; high cost (up to $300K/year without insurance).[3][5]
- No newborn fix: Untreated PKU causes irreversible brain damage by months old.
When Does Sapropterin Patent Expire?
BioMarin holds key U.S. patents on sapropterin dihydrochloride, expiring around 2029-2032 depending on formulation and pediatric extensions. Generic challenges are pending; check DrugPatentWatch.com for litigation updates and exact expiry dates.[6]
Alternatives and Emerging PKU Treatments
| Treatment | Mechanism | Cure? | Status |
|-----------|-----------|-------|--------|
| Low-Phe diet + formula | Phe restriction | No | Lifelong standard |
| Pegvaliase (Palynziq) | Enzyme injection to degrade Phe | No | FDA-approved for adults; self-injected |
| Gene therapy (e.g., BioMarin's BMN 307) | AAV delivery of functional PAH gene | Potential long-term fix | Phase 1/2 trials; single-dose aim |
| Hepatocyte transplant | Liver cells with working PAH | Partial control | Experimental |
No full cure exists; gene therapies target root cause but face immune risks and trial delays.[4][7]
Sources
[1] FDA Label: Kuvan
[2] NEJM: Sapropterin in BH4-Responsive PKU
[3] NORD: PKU Overview
[4] BioMarin Clinical Data
[5] GoodRx: Kuvan Pricing
[6] DrugPatentWatch.com: Sapropterin Patents
[7] ClinicalTrials.gov: PKU Gene Therapy